Printer Friendly

PATENT ISSUED ON CORTEX'S SPECTRIN TECHNOLOGY FOR DETECTION OF BRAIN CELL DEGENERATION

 PATENT ISSUED ON CORTEX'S SPECTRIN TECHNOLOGY
 FOR DETECTION OF BRAIN CELL DEGENERATION
 IRVINE, Calif., June 3 /PRNewswire/ -- Cortex Pharmaceuticals Inc. (NASDAQ: CORX) today announced the issuance of U.S. Patent No. 5,118,606 relating to the use of spectrin as a marker for degeneration of brain cells. Spectrin is a protein found in many types of cells in the body and is an important component of the "cytoskeleton" or structural framework, of neurons.
 Cortex and University of California scientists discovered that spectrin breaks down in a unique and recognizable manner when brain cells degenerate, and that spectrin breakdown could therefore be used to detect the presence and extent of cell death. The company secured exclusive worldwide rights to the technology under a 1991 agreement with the University of California.
 According to Dr. Jay Glass, interim president and chief executive officer of Cortex, the technology is heavily utilized at the company in drug screening and as a tool to measure brain cell death in models for stroke and cardiac arrest. "The rapid progress in our program to develop a drug to limit brain damage following stroke has been due, in part, to the availability of a fast, simple spectrin-based assay to measure degenerative processes," said Glass. "We believe the assay can be developed into a clinical tool that would be used by physicians as an initial patient screen for neurodegeneration. It may also be applicable to monitoring the progress of neurodegenerative disorders, as well as the effectiveness of therapeutic intervention with neuroprotective drugs."
 Currently, suspected neurodegeneration is assessed primarily with imaging scans, which cost some $500 to $1,500 per procedure. Cortex is targeting development of a spectrin-based immunoassay that would detect the presence of neurodegenerative conditions at much lower cost. Glass indicated that Cortex intends to collaborate with a diagnostic company to complete test development and commercialize a spectrin-based diagnostic.
 Cortex is a neurological drug discovery company that is developing products for the treatment and diagnosis of age-related diseases and disorders of the brain.
 -0- 6/3/92
 /CONTACT: Scott Hagen, VP and CFO of Cortex Pharmaceuticals, 714-727-3157; or Fred Spar of Kekst & Co., 212-593-2655, for Cortex Pharmaceuticals/
 (CORX) CO: Cortex Pharmaceuticals Inc. ST: California IN: MTC SU:


KJ-EH -- LA005 -- 6507 06/03/92 09:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1992
Words:378
Previous Article:DYNATRONICS ANNOUNCES MAJOR NEW PRODUCT; THE DYNATRON 400
Next Article:MEDTRONIC EARNINGS INCREASE 21.1 PCT. ON STRONG MARKET SHARE TRENDS
Topics:


Related Articles
Cortex Receives U.S. Notice of Allowance on Broad Calpain Inhibitor Patent
Cortex Receives Additional AMPAKINE Patent.
Cortex Receives Broad Patent Claims for Drugs to Improve Memory and Cognition.
Cortex Receives Broad Patent Claims for Drugs to Improve Memory and Cognition.
Cortex receives additional Ampakine patents and notices of allowance.
Cortex Pharma receives notice of allowance of European patent.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters